SIC 2835 – In Vitro and In Vivo Diagnostic Substances
Valuation | |
---|---|
Market Cap ($M) | 294.26 |
Enterprise Value ($M) | 304.04 |
Book Value ($M) | 82.39 |
Book Value / Share | 1.55 |
Price / Book | 3.57 |
NCAV ($M) | 6.40 |
NCAV / Share | 0.12 |
Price / NCAV | 45.97 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.24 |
Return on Assets (ROA) | -0.21 |
Return on Equity (ROE) | -0.30 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.21 |
Current Ratio | 3.82 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 42.78 |
Assets | 118.77 |
Liabilities | 36.38 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 37.74 |
Operating Income | -26.15 |
Net Income | -26.75 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -12.39 |
Cash from Investing | -27.27 |
Cash from Financing | 14.89 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D | Telegraph Hill Partners IV, L.P. | 70.80 | 47.21 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
129,093 | 390,338 | 33.07 | |
135,657 | 544,784 | 24.90 | |
102,369 | 399,644 | 25.62 | |
197,430 | 508,038 | 38.86 | |
(click for more detail) |
Similar Companies | |
---|---|
TARA – Protara Therapeutics, Inc. | TBPH – Theravance Biopharma, Inc. |
TCRX – TScan Therapeutics, Inc. | TLPH – Talphera, Inc. |
TNGX – Tango Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io